Trends Driving the Use of ePRO in Oncology Trials

Patient-reported outcomes (PROs), long relegated to the sidelines of clinical research and new drug application evidence, are becoming more critical to regulators’ decision making in oncology. This article explains why this is the case, what specifically regulators are requesting, and how sponsors can comply most efficiently.

Click here to read the full article.

Share